EFPIA has published new data from two reports, which provide granular detail about why new medicines are available in some countries but not in others.
The third European Access Hurdles Portal report is part of an industry-led initiative to increase visibility regarding the root causes of unavailability of innovative medicines in Europe.
With 100% participation from EFPIA members and covering 94 medicines approved between January 2021 and June 2024, the data clearly shows that the majority of delays (69%) occur after companies have filed and are awaiting a decision from a Member State.